IRIS
CANTINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.570
EU - Europa 383
AS - Asia 60
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 2.017
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.570
IT - Italia 105
IE - Irlanda 94
SE - Svezia 84
GB - Regno Unito 34
SG - Singapore 26
UA - Ucraina 21
DE - Germania 17
IN - India 16
CN - Cina 12
BE - Belgio 11
FR - Francia 7
DK - Danimarca 4
JP - Giappone 4
EU - Europa 3
RO - Romania 3
KR - Corea 2
AU - Australia 1
FI - Finlandia 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 2.017
Salva come PNG Salva come JPEG
Città #
Chandler 292
Des Moines 268
Ashburn 109
Fairfield 108
Dublin 89
New York 87
Ann Arbor 53
Wilmington 49
Woodbridge 46
Seattle 45
Cambridge 36
Houston 36
Jacksonville 35
Lawrence 34
Princeton 34
Turin 31
San Mateo 27
Boardman 24
San Diego 24
Pune 16
Washington 16
Los Angeles 12
Brussels 11
London 11
Beijing 7
Redmond 6
Falls Church 5
Arnold 4
Civitanova Marche 3
Fermignano 3
Kilburn 3
Prescot 3
Tolentino 3
Ancona 2
Bellante 2
Caserta 2
Castelraimondo 2
Centro 2
Fabriano 2
Kagoya 2
Milan 2
Norwalk 2
Recanati 2
Shenzhen 2
Slobozia 2
Acerra 1
Acton 1
Bolton 1
Brisbane 1
Chiswick 1
Dangan 1
Falconara Marittima 1
Falkenstein 1
Genzano di Roma 1
Hounslow 1
Islington 1
Jesi 1
Limido Comasco 1
Long Beach 1
Mantova 1
Mestre 1
New Bedfont 1
Phoenix 1
Redwood City 1
Saint Petersburg 1
San Costanzo 1
Southwark 1
Stockholm 1
Tower Hamlets 1
Wuhan 1
Totale 1.579
Salva come PNG Salva come JPEG
Nome #
Are liver nested stromal epithelial tumors always low aggressive? 106
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 95
Optimal management of resected gastric cancer 94
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 88
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 83
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 83
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 80
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 79
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 75
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 73
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 64
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 63
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 61
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 59
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 59
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 59
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 57
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 57
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 56
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 55
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 54
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience 51
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 49
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 49
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 49
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 46
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 46
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 38
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078] 35
Cancer patient perspective in the arena of COVID-19 pandemic 32
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 31
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 29
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 28
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 24
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 23
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 20
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 13
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 11
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 3
Totale 2.077
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.667
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.667
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 3 2 2
2019/202059 2 1 2 1 5 1 6 4 5 13 6 13
2020/2021360 7 13 60 57 33 6 8 31 25 24 53 43
2021/2022296 3 28 5 6 18 36 13 18 51 17 38 63
2022/2023939 58 97 43 72 47 316 0 46 151 9 80 20
2023/2024384 72 12 31 35 52 154 3 9 0 16 0 0
Totale 2.077